Prolactin synthesis by lymphocytes from patients with systemic sclerosis

Biomedicine and Pharmacotherapy

Volumn 60, Issue 4, 2006, Pages 152-155

  Czuwara Ladykowska, Joanna ^a   Sicinska, Justyna ^a   Olszewska, Malgorzata ^b   Uhrynowska Tyszkiewicz, Izabela ^b   Rudnicka, Lidia ^a,c  

^a Department of Dermatology CSK MSWiA ^*  (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Interleukin 2; Scleroderma; T cells

Indexed keywords

PROLACTIN; PROLACTIN RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CELL LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN SYNTHESIS; SEX RATIO; SUPERNATANT; SYSTEMIC SCLEROSIS; BIOSYNTHESIS; HYPERPROLACTINEMIA; METABOLISM; MIDDLE AGED;

ADULT; FEMALE; HUMANS; HYPERPROLACTINEMIA; LYMPHOCYTES; MALE; MIDDLE AGED; PROLACTIN; SCLERODERMA, SYSTEMIC;

EID: 33745012620     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.02.007     Document Type: Article

References (13)

1. Generini S., Fiori G., Moggi Pignone A., Matucci-Cerinic M., and Cagnoni M. Systemic sclerosis. A clinical overview. Adv. Exp. Med. Biol. 455 (1999) 73-83
2. Varga J., Rudnicka L., and Uitto J. Connective tissue in scleroderma. Clin. Dermat. 12 387 (1994) 3-96
3. Steen VD. Pregnancy in women with systemic sclerosis. Obstet. Gynecol. 1999;94: 15-20.
4. La Montagna G., Baruffo A., Pasquali D., Bellastella A., Tirri G., and Sinisi A.A. Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis. Rheumatology 40 (2001) 310-314
5. McMurray R.W. Bromocriptine in rheumatic and autoimmune diseases. Semin. Arthritis Rheum. 31 (2001) 21-32
6. Peeva E., Venkatesh J., Michael D., and Diamond B. Prolactin as a modulator of B cell function: implications for SLE. Biomed. Pharmacother. 58 (2004) 310-319
7. Shahin A.A., Abdoh S., and Abdelrazik M. Prolactin and thyroid hormones in patients with systemic sclerosis: correlation with disease manifestations and activity. Z. Rheumatol. 61 (2002) 703-709
8. Kucharz E.J., Jarczyk R., Jonderko G., Rubisz-Brzezińska J., and Brzezińska-Wcisło L. High serum level of prolactin in patients with systemic sclerosis. Clin. Rheumatol. 15 (1996) 314
9. Straub R.H., Zeuner M., Lock G., Scholmerich J., and Lag B. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br. J. Rheumatol. 36 (1997) 426-432
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23 (1980) 581-590
11. Rudnicka L., Majewski S., and Blaszczyk M. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum. 35 (1992) 771-775
12. La Montagna G., Meli R., Criscuolo T., D×Angelo S., and Valentini G. Bioactivity of prolactin in systemic sclerosis. Clin. Exp. Rheumatol. 22 (2004) 145-150
13. Lis A., and Brzezinska-Wcisło L. Interleukin-2 and interleukin-6 as serum markers for disease progression in systemic sclerosis. Pol. Merkuriusz Lek. 11 (2001) 206-209